GleamWall
中文EN

SIGY Sigyn Therapeutics, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1642159 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY19.3%
TTM EPS YoY39.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,144.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets4,464.7%
Debt / equity—
Current ratio0.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-811.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-312023Q4*2023-12-31
Income statement
Revenue————————
R&D expense$29,681$7,482$8,842$94,096$206,161$240,429$232,593$215,933
SG&A expense$306,796$412,023$487,041$495,744$564,683$324,868$359,541$613,746
Operating income-$386,529-$469,513-$546,059-$478,010-$808,458-$602,805-$629,972-$717,236
Pretax income-$578,503-$1.45M-$668,564-$522,818-$1.20M-$862,383-$758,088-$1.18M
Net income-$578,503-$1.45M-$668,564-$522,818-$1.20M-$862,383-$758,088-$1.18M
EBITDA-$386,529-$469,513-$544,696-$476,647-$807,095-$601,441-$628,449-$715,626
EPS (basic)-0.36-0.90-0.42—-0.94-0.70-0.62—
EPS (diluted)-0.36-0.90-0.42—-0.94-0.70-0.62—
Weighted avg. shares (diluted)1.61M1.61M1.61M—1.27M1.24M1.23M—
Balance sheet
Cash & equivalents$85,571$459$12,895$12,144$164,788$53,644$32,838$11,690
Inventory————$50,000$50,000$50,000$50,000
Current assets$85,571$1,759$68,095$21,244$269,108$146,376$134,428$118,063
PP&E, net——$8,322$9,685$11,048$12,411$13,773$15,296
Total assets$135,571$51,759$244,309$213,719$427,438$320,165$323,295$321,806
Current liabilities$3.99M$5.49M$5.15M$4.61M$4.28M$3.90M$4.23M$3.61M
Short-term debt$720,687$262,062$212,920$0————
Long-term debt$3.55M$2.49M$2.40M$2.02M$2.00M$2.01M$2.78M$2.51M
Total debt$4.27M$2.75M$2.61M$2.02M$2.00M$2.01M$2.78M$2.51M
Total liabilities$6.05M$5.49M$5.19M$4.67M$4.35M$3.99M$4.34M$3.73M
Shareholders' equity-$5.92M-$5.44M-$4.95M-$4.46M-$3.92M-$3.67M-$4.02M-$3.41M
Net debt$4.18M$2.75M$2.60M$2.01M$1.83M$1.96M$2.75M$2.50M
Shares outstanding1.61M1.61M1.61M1.61M1.42M1.26M1.22M1.29M
Cash flow statement
Operating cash flow-$199,326-$152,436-$294,446-$290,218-$163,812-$182,794-$235,612-$127,894
Financing cash flow$284,438$140,000$295,197$137,574$274,956$203,600$256,760$75,000
Depreciation & amortization$0$0$1,363$1,363$1,363$1,364$1,523$1,610
Stock-based compensation$50,000$50,000$50,000$37,500$37,500$37,500$37,500$103,058

Free plan shows the latest 8 periods; Pro shows all 44 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.